Articles and Videos
Peer-reviewed Publication: Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway
A peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International...
InMed Presents at the 2023 Emerging Growth Conference
InMed’s CEO, Mr. Eric A. Adams, presents at the Emerging Growth Conference. This virtual presentation was given on March 8th, 2023. In the presentation, Mr....
Neurodegenerative Disease Studies of Cannabinoid Analogs
InMed's Senior VP, Preclinical Research and Development, Dr. Eric Hsu, shares results from early neurodegenerative disease studies demonstrating how specific cannabinoids induced neuroprotective effects and...
Source:
Tribe Public
Why explore cannabinoids as potential therapeutic targets for neurodegenerative diseases?
In this video, Eric A. Adams explains how the body’s endocannabinoid system has natural cannabinoid receptors throughout the body that interact with cannabinoids and are...
Source:
The Dales Report
The Dales Report: InMed Pharmaceuticals Clinical Trial Program Moving Forward In 2023
InMed's CEO, Eric A. Adams, joins The Dales Report webcast to talk about the 2023 plans for the company's rare cannabinoid programs in epidermolysis bullosa...
Source:
The Dales Report
The Dales Report: InMed Focused On Clinical Trial Success In 2023
The Dales Report's Shadd Dales interviews InMed CEO, Eric A. Adams, to talk about the company's upcoming pharmaceutical development plans for 2023. Eric speaks about...
Source:
The Dales Report
